DEPO-ELIGARD 45 mg

DRUG3 trials

Sponsors

Ziekenhuis Aan De Stroom, UZ Leuven, Cancer Research Antwerp

Conditions

Oligorecurrent hormone-sensitive prostate cancer patientsProstate CancerProstate cancer

Phase 2

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

RecruitingCTIS2022-501551-90-00

Ziekenhuis Aan De StroomProstate cancer

Start: 2023-12-13Target: 583Updated: 2026-01-23

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

RecruitingNCT06282588

Cancer Research AntwerpProstate Cancer

Start: 2023-12-13End: 2030-12-31Target: 493Updated: 2026-03-19

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

Related Papers

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial.

2025-09-25